Casting a spell: The Killer50 Magic Circle is unveiled

5 November 2020 – The operating landscape has changed remarkably for many life science and technology businesses in the Cambridge Cluster since the March 23 lockdown and subsequent restrictions affecting lifestyle and working practices. Read full article

Cambridge companies help develop Covid antibody cocktail

1 November 2020 – The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19, has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody cocktail. Read full article

Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium

29 October 2020 – The UK BIA Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool […]

UK-based Alchemab partners with Amii to accelerate the development of novel therapeutics to cure disease

29 September 2020 – Alchemab, a UK biotech company focused on harnessing the power of adaptive immune systems to cure disease, announced a strategic partnership with the Alberta Machine Intelligence Institute (Amii) to accelerate its adoption of artificial intelligence. Read full article

OBN Awards – Announcement of 2020 Finalists

11 September 2020 – OBN Award Finalists Read full article

Agile start-ups partner with academics to find COVID-19 solutions

16 July 2020 – Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19. Even before the lockdown began, Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics all quickly redirected their scientific expertise and business plans. These rapid innovations were achieved through collaborations with nearby experts, […]

Illumina unveils first Cambridge cohort for global genomics accelerator

23 June 2020 – Two Cambridge companies fly the flag for the UK cluster in the first global cohort of Illumina’s genomics accelerator. Alchemab Therapeutics and Tailor Bio are among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK. Read full article

Illumina Accelerator Welcomes First Global Cohort of Genomics Startups

23 June 2020 – Illumina, Inc. has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups. Read full article

Alchemab: One for the future and another first for Cambridge

4 June 2020 – A novel Cambridge UK life science startup – Alchemab Therapeutics – looks set for global glory by identifying and harnessing the power of naturally protective antibodies to combat a broad range of hard-to-treat diseases. Read full article

Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures

20 May 2020 – Alchemab’s publication illustrating progress in understanding patients’ immune responses to COVID19 which will help inform vaccination and antibody therapeutics. Read full article